Galactosylation variations in marketed therapeutic antibodies.

@article{Raju2012GalactosylationVI,
  title={Galactosylation variations in marketed therapeutic antibodies.},
  author={T Shantha Raju and Robert E. Jordan},
  journal={mAbs},
  year={2012},
  volume={4 3},
  pages={385-91}
}
There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Chinese hamster ovary (CHO) cells or mouse myeloma cells as the expression system. Because CHO and mouse myeloma cells are mammalian cells, rIgGs produced in these cell lines are typically N… CONTINUE READING